Compare ARK Genomic Revolution ETF (ARKG) vs Veritone Inc (VERI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Veritone Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while Veritone Inc trades at $1.17 (market cap $109.22M). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | VERI | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $8.39 |
52-Week Low | $23.09 | $1.18 |
Market Cap | — | $109.22M |
Enterprise Value | — | $141.25M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Veritone (VERI) trades at $1.18, down 1.67% on the day, amid a bearish technical outlook and significant financial challenges. The company reported a net loss of $111.73 million in 2025, with negative profit margins and cash flow from operations. Recent news is dominated by multiple securities class action lawsuits alleging accounting irregularities, with a key deadline of July 20, 2026.
The outlook remains highly risky due to persistent losses, legal overhangs, and negative investor sentiment. While analyst consensus suggests substantial upside to a $5.25 price target, fundamental weaknesses and ongoing litigation present severe headwinds for shareholder value recovery in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
